Ascendis Pharma A/SNASDAQ:ASND
- LAST PRICE136.3800
- TODAY'S CHANGE (%)0.9800 (0.7238%)
- Bid / Lots130.2700/ 1
- Ask / Lots142.8000/ 1
- Open / Previous Close136.1100 / 135.4000
- Day Range
- 52 Week Range
- Volume256,715
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ASND |
|---|---|---|
| 09:32 ET | 1874 | 137.61 |
| 09:34 ET | 400 | 137.54 |
| 09:38 ET | 500 | 134.35 |
| 09:39 ET | 100 | 135.23 |
| 09:41 ET | 206 | 136.655 |
| 09:43 ET | 200 | 134.37 |
| 09:45 ET | 300 | 134.39 |
| 09:48 ET | 500 | 134.43 |
| 09:54 ET | 100 | 134.535 |
| 09:56 ET | 200 | 134.41 |
| 09:59 ET | 100 | 135.15 |
| 10:01 ET | 925 | 134.81 |
| 10:12 ET | 200 | 135.03 |
| 10:14 ET | 100 | 135.57 |
| 10:21 ET | 679 | 135.575 |
| 10:24 ET | 837 | 134.78 |
| 10:26 ET | 1376 | 135.285 |
| 10:28 ET | 400 | 135.38 |
| 10:30 ET | 530 | 135.0979 |
| 10:32 ET | 1110 | 135.7 |
| 10:33 ET | 400 | 135.3 |
| 10:35 ET | 385 | 135.62 |
| 10:37 ET | 1798 | 135.5 |
| 10:39 ET | 326 | 135.42 |
| 10:42 ET | 300 | 135.94 |
| 10:44 ET | 369 | 136.2704 |
| 10:46 ET | 1120 | 136.115 |
| 10:50 ET | 1816 | 136.2 |
| 10:51 ET | 200 | 136.19 |
| 11:02 ET | 100 | 136.13 |
| 11:08 ET | 470 | 136.125 |
| 11:11 ET | 335 | 135.72 |
| 11:13 ET | 200 | 135.76 |
| 11:15 ET | 400 | 135.41 |
| 11:20 ET | 200 | 134.81 |
| 11:24 ET | 200 | 134.58 |
| 11:27 ET | 333 | 134.595 |
| 11:29 ET | 200 | 134.9 |
| 11:31 ET | 1581 | 134.91 |
| 11:33 ET | 100 | 134.96 |
| 11:36 ET | 100 | 134.66 |
| 11:38 ET | 2372 | 134.61 |
| 11:44 ET | 100 | 134.445 |
| 11:45 ET | 300 | 134.26 |
| 11:49 ET | 100 | 134.67 |
| 11:54 ET | 100 | 134.58 |
| 12:00 ET | 770 | 134.61 |
| 12:03 ET | 100 | 134.84 |
| 12:05 ET | 140 | 134.37 |
| 12:07 ET | 5946 | 134.425 |
| 12:12 ET | 124 | 134.79 |
| 12:14 ET | 400 | 133.75 |
| 12:16 ET | 100 | 133.935 |
| 12:18 ET | 100 | 133.785 |
| 12:27 ET | 300 | 134.06 |
| 12:34 ET | 400 | 134.06 |
| 12:38 ET | 400 | 134.04 |
| 12:41 ET | 200 | 133.82 |
| 12:57 ET | 367 | 134.08 |
| 01:01 ET | 200 | 133.975 |
| 01:10 ET | 200 | 133.96 |
| 01:12 ET | 597 | 133.81 |
| 01:15 ET | 180 | 133.9 |
| 01:19 ET | 588 | 133.775 |
| 01:21 ET | 200 | 133.58 |
| 01:28 ET | 100 | 133.42 |
| 01:30 ET | 200 | 133.24 |
| 01:33 ET | 200 | 133.205 |
| 01:35 ET | 200 | 133.015 |
| 01:37 ET | 100 | 133 |
| 01:46 ET | 200 | 133.12 |
| 01:48 ET | 200 | 133.29 |
| 01:50 ET | 337 | 133.5 |
| 01:51 ET | 200 | 133.29 |
| 02:06 ET | 116 | 133.65 |
| 02:09 ET | 100 | 133.74 |
| 02:11 ET | 152 | 134.2 |
| 02:13 ET | 180 | 133.995 |
| 02:20 ET | 100 | 134.16 |
| 02:24 ET | 300 | 134 |
| 02:26 ET | 310 | 134.0521 |
| 02:27 ET | 204 | 134.26 |
| 02:31 ET | 133 | 134.35 |
| 02:42 ET | 100 | 134.235 |
| 02:44 ET | 543 | 133.9 |
| 02:45 ET | 300 | 134 |
| 02:47 ET | 110 | 133.7 |
| 02:49 ET | 100 | 133.72 |
| 02:51 ET | 425 | 133.605 |
| 02:54 ET | 100 | 133.71 |
| 02:56 ET | 101 | 133.63 |
| 02:58 ET | 311 | 133.605 |
| 03:00 ET | 120 | 133.695 |
| 03:02 ET | 2299 | 134.4 |
| 03:03 ET | 563 | 134.0991 |
| 03:05 ET | 300 | 134.07 |
| 03:09 ET | 24130 | 134.97 |
| 03:12 ET | 200 | 135.235 |
| 03:14 ET | 1154 | 134.56 |
| 03:16 ET | 300 | 134.98 |
| 03:18 ET | 200 | 135.2 |
| 03:20 ET | 200 | 135.47 |
| 03:21 ET | 100 | 135.185 |
| 03:25 ET | 131 | 135.24 |
| 03:30 ET | 200 | 135.36 |
| 03:32 ET | 850 | 134.83 |
| 03:34 ET | 400 | 134.85 |
| 03:36 ET | 400 | 134.9 |
| 03:38 ET | 1430 | 135.5 |
| 03:39 ET | 390 | 135.6 |
| 03:41 ET | 500 | 135.51 |
| 03:43 ET | 1190 | 135.28 |
| 03:45 ET | 255 | 135.54 |
| 03:48 ET | 1130 | 135.34 |
| 03:50 ET | 1158 | 135.48 |
| 03:52 ET | 1807 | 135.92 |
| 03:54 ET | 1519 | 136.18 |
| 03:56 ET | 4715 | 135.565 |
| 03:57 ET | 1360 | 135.71 |
| 03:59 ET | 8936 | 136.38 |
Jun 25, 2024
DJ Ascendis Pharma Raised to Buy From Hold by TD Cowen, from 7:45AM ET on Tuesday Jun 25, 2024 by Dow Jones
7:45AM ET on Tuesday Jun 25, 2024 by Dow Jones
Jun 24, 2024
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024, from 4:45PM ET on Monday Jun 24, 2024 by Dow Jones
4:45PM ET on Monday Jun 24, 2024 by Dow Jones
Jun 4, 2024
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024, from 4:01PM ET on Monday Jun 03, 2024 by Dow Jones
4:01PM ET on Monday Jun 03, 2024 by Dow Jones
May 31, 2024
DJ Ascendis Pharma Initiated at Buy by Stifel, from 6:14AM ET on Friday May 31, 2024 by Dow Jones
6:14AM ET on Friday May 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ascendis Pharma A/S | 7.7B | -14.3x | --- |
Legend Biotech Corp | 8.2B | -17.0x | --- |
Intra-Cellular Therapies Inc | 7.5B | -59.4x | --- |
Blueprint Medicines Corp | 6.5B | -22.4x | --- |
Vaxcyte Inc | 8.2B | -17.9x | --- |
Insmed Inc | 11.2B | -12.8x | --- |
Company Information
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Contact Information
- Headquarters
- Tuborg Boulevard 12HELLERUP, Denmark 2900
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Albert Cha
- President, Chief Executive Officer, Executive Director, Member of the Executive Board
- Jan Moller Mikkelsen
- Chief Financial Officer, Executive Vice President, Member of the Executive Board
- Scott Smith
- Executive Vice President, Chief Administrative Officer
- Lotte Soenderbjerg
- Executive Vice President, Global Chief Commercial Officer
- Camilla Hartvig
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.7B |
|---|---|
Revenue (TTM) | $352.1M |
Shares Outstanding | 58.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-9.51 |
Book Value | $-2.70 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | 22.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -109.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
